Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Deborah J. Wexler MD, MSc Associate Editor

Richard E. Pratley MD Associate Editor

See All Experts

featured

Published in Diabetes

Journal Scan / Research · September 15, 2016

LixiLan Decreases HbA1c Levels and Body Weight in Diabetic Patients

Diabetes Care

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Richard Pratley MD

Diabetes Care

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled With Oral Agents: The LixiLan-O Randomized Trial

Diabetes Care 2016 Aug 15;[EPub Ahead of Print], J Rosenstock, R Aronson, G Grunberger, M Hanefeld, P Piatti, P Serusclat, X Cheng, T Zhou, E Niemoeller, E Souhami, M Davies

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

LixiLan Decreases HbA1c Levels and Body Weight in Diabetic Patients

Additional Info

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled With Oral Agents: The LixiLan-O Randomized Trial

Further Reading

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Potential Off-Label Indication of Metformin for Ischaemic Stroke

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Effect of Long-Term Glycemic Burden on the Incidence of Diabetic Foot Ulcers

Weight Maintenance Using Cost-Effective Antiobesity Medications After 1 Year of GLP-1 Receptor Agonist Therapy

Trends in the Incidence of Young Adult–Onset Diabetes by Diabetes Type

Prognosis of Severe Hypoglycaemia and Diabetic Ketoacidosis in Adults Presenting to an Emergency Department

Recently Updated